Ask AI
ProCE Banner Activity

PROTAC ER Degraders in ER+/HER2- MBC Progressing After Endocrine Therapy: Emerging Mechanisms and Implications for Clinical Practice on the Horizon

Clinical Thought

This expert-led commentary summarizes the latest data and clinical pearls with PROTAC ER degraders and future application for ER+/HER2- MBC that has progressed after endocrine therapy.

Released: January 21, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc. and Arvinas.

Arvinas

Pfizer Inc.

Disclosure

Primary Author

Erika Hamilton, MD

Chair, Breast Executive Committee
Director, Breast Cancer Research Program
Sarah Cannon Research Institute
SCRI Oncology Partners
Nashville, Tennessee

Erika Hamilton, MD: researcher (paid to institution): AbbVie, Acerta, Accutar Biotechnology, ADC Therapeutics, AKESOBIO Australia, Amgen, Aravive, ArQule, Artios, Arvinas, AstraZeneca, AtlasMedx, BeiGene, Black Diamond, Bliss BioPharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Cascadian Therapeutics, Clovis, Compugen, Context Therapeutics, Cullinan, Curis, CytomX, Daiichi Sankyo, Dana-Farber Cancer Institute, Dantari, Deciphera, Duality Biologics, eFFECTOR Therapeutics, Eisai, Ellipses, Elucida Oncology, EMD Serono, Fochon, FujiFilm, G1 Therapeutics, Gilead Sciences, H3 Biomedicine, Harpoon, Hutchinson MediPharma, Immunogen, Immunomedics, Incyte, Infinity, Inspirna, InventisBio, Jacobio, Karyopharm, K-Groub Beta, Kind, Leap, Lilly, Loxo Oncology, Lycera, Mabspace Biosciences, MacroGenics, MedImmune, Mersana, Merus, Millennium, Molecular Templates, Myriad Genetic Laboratories, Novartis, Nucana, Olema, OncoMed, Oncothyreon, ORIC Pharmaceuticals, Orinove, Orum, Pfizer, PharmaMar, Pieris, Pionyr Immunotherapeutics, Plexxikon, Prelude, Profound Bio, Radius Health, Regeneron, Relay Therapeutics, Repertoire Immune Medicine, Rgenix, Roche/Genentech, SeaGen, Sermonix, Shattuck, Silverback, StemCentRx, Stemline, Sutro, Syndax, Syros, Taiho, TapImmune, Tesaro, Tolmar, Torque, Treadwell, Verastem, Zenith Epigenetics, Zymeworks; consultant/advisor (paid to institution): Accutar Biotechnology, Arvinas, AstraZeneca, Circle, Daiichi Sankyo, Entos, Gilead Sciences, IQVIA, Janssen, Jazz, Jefferies, Johnson & Johnson, Lilly, Medical Pharma Services, Mersana, Olema, Pfizer, Roche/Genentech, Shorla, Stemline, Tempus Labs, Theratechnologies, Tubulis, Zentalis.